Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Circulation|March 3, 2010
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trialHertzel C Gerstein, Robert E Ratner, Christopher P Cannon, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 23, 2012
The SURTAVI model: proposal for a pragmatic risk stratification for patients with severe aortic stenosisNicolas M van Mieghem, Stuart J Head, Robert M A van der Boon, et al.
Lancet (London, England)|November 2, 2015
Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trialManel Sabaté, Salvatore Brugaletta, Angel Cequier, et al.
Circulation|May 2, 2007
Clinical end points in coronary stent trials: a case for standardized definitionsDonald E Cutlip, Stephan Windecker, Roxana Mehran, et al.
International Journal of Cardiovascular Interventions|December 10, 2002
Clinical and angiographic results with the beStent: the Registry for Optimal beStent Evaluation (ROSE) trialHarry Suryapranata, Jean L Boland, Michael Pieper, et al.
Circulation. Cardiovascular Interventions|December 25, 2009
Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2Bernard Chevalier, Sigmund Silber, Seung-Jung Park, et al.
American Heart Journal|November 29, 2016
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO studyStephan Windecker, Jan Tijssen, Gennaro Giustino, et al.
Heart (British Cardiac Society)|November 27, 2014
Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarctionYao-Jun Zhang, Javaid Iqbal, Stephan Windecker, et al.
American Heart Journal|June 20, 2006
The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phaseAndrew T L Ong, Patrick W Serruys, Frederick W Mohr, et al.
JACC. Cardiovascular Interventions|August 20, 2011
2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practiceVolker Klauss, Patrick W Serruys, Thomas Pilgrim, et al.
Pageof 9